Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
A phase 1/2 trial of Fludarabine, Cyclophosphamide, Nivolumab in mesothelioma and ovarian cancer, run by TCR2 Therapeutics, active and no longer recruiting.
Overview
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer is a phase 1/2 interventional study registered as NCT03907852 by TCR2 Therapeutics, with 57 participants enrolled, started 2019-04-15 and due to reach its primary completion in 2024-11-19. Interventions recorded: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab. Conditions listed: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide, Ovarian cancer.
- TrialStudy of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur
Shares Cyclophosphamide, Ovarian cancer, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA 2-part Phase 1/2 Open-label Trial on ODM-212
Shares Ipilimumab, Mesothelioma, Nivolumab, Small-cell lung cancer.
- TrialDual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Shares Fludarabine, Cyclophosphamide, Mesothelioma.
- TrialStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Shares Nivolumab, Ovarian cancer, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.